hero image
Patients & Families

Together, we can transform the status quo for kidney disease treatment.

We are working vigorously alongside kidney experts and patient advocates to pioneer a new approach to identify the genetic and environmental causes of kidney diseases in hope of discovering and developing meaningful treatments aimed at getting to the root cause of your disease.

Our ongoing clinical trials


The purpose of our Phase 2 trial, TRACTION-2, is to determine if our once-daily, oral, investigational precision medicine, GFB-887, is beneficial for people with high levels of protein in their urine due to focal segmental glomerulosclerosis (FSGS), diabetic nephropathy (DN) or treatment resistant minimal change disease (TR-MCD). Patients participating in TRACTION-2 may be eligible to participate in an open-label, long-term extension trial.

To learn more about TRACTION-2, visit TractionClinicalTrial.com or clinicaltrials.gov

Traction Program



The purpose of our Phase 1 trial is to determine if our investigational precision medicine, GFB-024, is safe and well tolerated in overweight and obese healthy volunteers.

For more information about the clinical trial design, please visit: www.clinicaltrials.gov (NCT04880291).

About the Goldfinch Bio Halo

You may have noticed the halo symbol on this website and across our social media pages, too. Here’s why it’s so meaningful to us.

Because of the current lack of therapeutic options, many people with kidney disease follow the same trajectory.  They progress from disease onset to end-stage kidney disease and, ultimately, dialysis and transplantation, significantly impacting their quality of life.

The halo symbolizes our goal to protect people with kidney disease from following this path by delivering disease-modifying precision medicines.

Patient organizations

Learn more about some of the organizations working on behalf of you and your loved ones:

Expanded access policy

At Goldfinch Bio, we are committed to developing safe and effective disease-modifying precision medicines to improve the quality of life for individuals living with kidney diseases and their families. Our goal is to provide access to our investigational drugs, at the appropriate time and in a clinically appropriate manner. Toggle

It is our duty to carefully evaluate the safety and efficacy of any of our investigational precision medicine product candidates. We believe that clinical trials are the best and most appropriate way to do that. The process is a collaborative effort, and we will work closely with researchers, physicians, clinical trial site teams, people living with kidney diseases and their families to conduct our studies efficiently and effectively. When successful, data from these studies form the basis of regulatory (i.e. U.S. Food and Drug Administration, European Medicine Agency, or other similar regulatory agencies) approvals, which ensure the most equitable and sustainable access to our precision medicines for the people who need them.

We know that people living with kidney diseases and their families are counting on us to potentially extend and improve their quality of life. Given this, we understand that some people living with kidney diseases and their families may be interested in accessing our investigational precision medicine product candidates prior to regulatory approval, and outside of the clinical trial setting, through an expanded access program (sometimes referred to as “early access” or “compassionate use”). Goldfinch Bio does not offer programs that allow access to our precision medicine product candidates prior to regulatory approval. For now, participating in a clinical trial is the only way to access our precision medicine product candidates.

More information about Goldfinch Bio’s current clinical trials is available above in the section titled “Information about our ongoing clinical trials.” If you have additional questions, please talk to your doctor or contact earlyaccessprogram@goldfinchbio.com. We plan to acknowledge receipt of requests sent to this email address within five business days.